Thrombolytic Therapy in Normotensive Patients with Pulmonary Embolism (Data from the Retrospective Study)

Background. The thrombolytic therapy is absolutely recommended for patients in shock or hypotension because the benefits are clearly outweighing the risks. However, in hemodynamically stable patients, including those with acute right ventricular dysfunction and/or myocardial damage, thrombolysis has a significantly lower evidence level.

Aim. To study the criteria based on which doctors decide to conduct thrombolytic therapy in normotensive patients in real clinical practice according to the retrospective data.

Material and methods. A single-center retrospective cohort study analyzed medical records of patients hospitalized in 2006-2017 with a verified diagnosis of pulmonary embolism (PE) and who had a systolic blood pressure >90 mm Hg at the time of admission.

Results. The present study population included 299 patients with a verified diagnosis of PE from 2006 to 2017 years. Patients were divided into two groups: with thrombolysis (group 1) and without thrombolysis (group 2). Logistic regression analysis showed that age younger than 60 years, the presence of varicose veins of the lower extremities, skin cyanosis, syncope in the debut of PE were independent clinical factors that significantly influence the doctor's decision to perform thrombolysis. Increased troponin I, right ventricular dysfunction, and the severity of PE according to the PESI score showed no significant impact on this decision. In-hospital mortality in the group 2 was 1.9% (5 patients), while there were no deaths in the group 1. But the analysis of the association of thrombolysis with survival was difficult to perform due to the low incidence of deaths and the small number of patients in the group with thrombolysis (odds ratio 0.34; 95% confidence interval 0.03-8.18; р=0.856). No major bleeding was registered in any group.

Conclusion. We were not able to clearly identify independent clinical or instrumental factors that influence the decision to perform thrombolysis in patients with PE outside the framework of evidence-based medicine. Further research is needed.

1. Ucar Y.E. Update on Thrombolytic Therapy in Acute Pulmonary Thromboembolism. Eurasian J Med. 2019;51(2):186-90. DOI:10.5152/eurasianjmed.2019.19291.

2. Konstantinides S.V., Meyer G., Becattini C., et al. 2019 ESC Guidelines for the Diagnosis and Management of Acute Pulmonary Embolism Developed in Collaboration With the European Respiratory Society (ERS): The Task Force for the Diagnosis and Management of Acute Pulmonary Embolism of the European Society of Cardiology (ESC). Eur Heart J. 2020;41(4):543-603. DOI:10.1093/eurheartj/ehz405.

3. Jiménez D., Lobo J.L., Barrios D., et al. Risk stratification of patients with acute symptomatic pulmonary embolism. Intern Emerg Med. 2016;11(1):11-8. DOI:10.1007/s11739-015-1388-0.

4. Dursunoglu N., Dursunoglu D., Yildiz A.I., et al. Evaluation of cardiac biomarkers and right ventricular dysfunction in patients with acute pulmonary embolism. Anatol J Cardiol. 2016;16:276-82. DOI:10.5152/akd.2014.5828.

5. Meyer G., Vicaut E., Danays T., et al. for the PEITHO Investigators. Fibrinolysis for Patients with Intermediate-Risk Pulmonary Embolism. N Engl J Med. 2014;370:1402-11. DOI:10.1056/NEJMoa1302097.

6. Howard L.S. Thrombolysis for PE: less is more? Thorax 2018;73(5):412-3. DOI:10.1136/thoraxjnl2017-211141.

7. Pruszczyk P. Have we found how to identify candidates for thrombolysis among normotensive patients with acute pulmonary embolism? Eur Respir J. 2016;47:1054-6. DOI:10.1183/13993003.02007-2015.

8. Yamashita Y., Murata K., Morimoto T. et al. Clinical outcomes of patients with pulmonary embolism versus deep vein thrombosis: From the COMMAND VTE Registry. Thromb Res. 2019;184:50-7. DOI:10.1016/j.thromres.2019.10.029.

9. Martin C., Sobolewski K., Bridgeman P., et al. Systemic Thrombolysis for Pulmonary Embolism: A Review. P T. 2016;41(12):770-5.

10. Tibbutt D. A., Davies J.A., Anderson J.A., et al. Comparison by Controlled Clinical Trial of Streptokinase and Heparin in Treatment of Life-threatening Pulmonary Embolism. British Med J. 1974;1:343-7. DOI:10.1136/bmj.1.5904.343.

11. Levine M., Hirsh J., Weitz J., et al. A randomized trial of a single bolus dosage regimen of recombinant tissue plasminogen activator in patients with acute pulmonary embolism. Chest. 1990;98(6):1473- 9. DOI:10.1378/chest.98.6.1473.

12. Dalla-Volta S., Palla A., Santolicandro A., et al. PAIMS 2: alteplase combined with heparin versus heparin in the treatment of acute pulmonary embolism. Plasminogen activator Italian multicenter study 2. J Am Coll Cardiol. 1992;20(3):520-6. DOI:10.1016/0735-1097(92)90002-5.

13. Chatterjee S., Chakraborty A., Weinberg I., et al. Thrombolysis for pulmonary embolism and risk of all-cause mortality, major bleeding, and intracranial hemorrhage: a meta-analysis. JAMA. 2014;311(23):2414-21. DOI:10.1001/jama.2014.5990.

14. Begieneman M.P., van de Goot F.R., van der Bilt I.A., et al. Pulmonary embolism causes endomyocarditis in the human heart. Heart. 2008;94:450-6. DOI:10.1136/hrt.2007.118638.

15. Sanchez O., Trinquart L., Caille V., et al. Prognostic factors for pulmonary embolism: the PREP Study, a prospective multicenter cohort study. Am J Respir Crit Care Med. 2010;181:168-73. DOI:10.1164/rccm.200906-0970OC.

16. Meyer G., Vicaut E., Danays T., et al. Fibrinolysis for patients with intermediate-risk pulmonary embolism. N Engl J Med. 2014;370:1402-11. DOI:10.1056/NEJMoa1302097.

17. Goldhaber S.Z., Haire W.D., Feldstein M.L., et al. Alteplase versus heparin in acute pulmonary embolism: randomized trial assessing right-ventricular function and pulmonary perfusion. Lancet. 1993;341(8844):507-11. DOI:10.1016/0140-6736(93)90274-k.

18. Holder T., Sullian A.E., Truong T., et al. Identification, diagnosis, treatment, and in-hospital outcomes of acute pulmonary embolism: Resutls from a single integrated health system. Am Heart J. 2019;216:136-42. DOI:10.1016/j.ahj.2019.06.016.

19. Keller K., Hobohm L., Ebner M., et al. Trends in thrombolytic treatment and outcomes of acute pulmonary embolism in Germany. Eur Heart J. 2020;41(4):522-9. DOI:10.1093/eurheartj/ehz236.